Epilepsy & Seizures
Photosensitive occipital lobe epilepsy
Dec. 03, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Nonconvulsive status …
- Updated 03.20.2024
- Released 08.20.2007
- Expires For CME 03.20.2027
Nonconvulsive status
Introduction
Overview
Status epilepticus is divided into two main subgroups: convulsive and nonconvulsive status epilepticus. Nonconvulsive status epilepticus is used to describe the group of seizures that are characterized by electrographic seizure activity on EEG associated with minimal or no motor movements, typically with associated alteration of awareness (from wandering to comatose). In this article, the authors describe the current thinking and controversies surrounding the definition and classification of nonconvulsive status epilepticus, as well as the difficulties in diagnosis. The authors also provide a treatment framework based on the current literature.
Key points
|
• Nonconvulsive status epilepticus is a state of ongoing seizure or intermittent seizure activity with minimal or no motor movements and alteration of consciousness. | |
|
• Nonconvulsive status epilepticus occurs both in ambulatory patients with epilepsy and in critically ill patients, especially those with acute brain injury. | |
|
• Ambulatory nonconvulsive status epilepticus (eg, absence nonconvulsive status epilepticus, focal status epilepticus with or without impaired awareness) carries a better outcome than nonconvulsive status epilepticus evolving from convulsive subtle status epilepticus and nonconvulsive status epilepticus in critically ill patients. | |
|
• There is no consensus on the best treatment strategy for nonconvulsive status epilepticus, and most of the recommendations are extrapolated from studies of convulsive status epilepticus. |
Historical note and terminology
In perhaps the earliest description of epilepsy with persistent altered consciousness, Trousseau in 1868 noted that repeated petit mal seizures might occur so frequently that one seizure would become confused with the next, simulating a continuous seizure that might persist for days. The term “status epilepticus” (“etat de mal”) was coined in 1824 (55). The idea that seizures could take on a prolonged, nonconvulsive form was highlighted by Bourneville who, in 1878, described two forms of status epilepticus: convulsive and meningitic. Meningitic status epilepticus is characterized by subtle or absent convulsions, coma, and autonomic abnormalities. These descriptions might well have constituted nonconvulsive status epilepticus, but the first electroclinical diagnosis occurred in 1945 when Lennox diagnosed absence status epilepticus with EEG correlate in his cousin. Nine years later, Penfield and Jasper described focal status epilepticus with intact awareness, aura continua, in a patient who suffered continual tingling of the left foot, and in 1958 Gastaut published the first case of focal status epilepticus with impaired awareness (22).
Nonconvulsive status epilepticus was initially described in ambulatory patients with chronic epilepsy, but with the evolution of EEG technology it has become evident that nonconvulsive status epilepticus is common among hospitalized patients, especially critically ill patients with unexplained altered mental status. The idea that electrographic seizures can frequently manifest solely as coma in hospitalized patients first became apparent in those presenting with convulsive status epilepticus. In 1984, Treiman and colleagues at UCLA coined the term “subtle status epilepticus” to describe the late “burned-out” stage of generalized convulsive status epilepticus as consisting of “nystagmus, eye blinking, and/or mild motor movements…with marked impairment of consciousness and continuous or nearly continuous, usually bilateral, ictal patterns on the EEG” (75). They also noted that some patients with this form of nonconvulsive status epilepticus may have had only an isolated convulsion (rather than convulsive status epilepticus) or may have never had a recognized convulsion (74). Subsequent authors have referred to this phenomenon as status epilepticus terminans (26) to distinguish it from other forms of nonconvulsive status epilepticus with little or no anteceding clinical manifestations. The widespread use of digital EEG and prolonged EEG monitoring has made it evident that nonconvulsive status epilepticus without preceding convulsive activity is the more common form of nonconvulsive status epilepticus in hospitalized patients, particularly in children and adults with acute brain injury and patients with severe systemic illness, such as sepsis (17; 21; 01).
Initially, nonconvulsive status epilepticus was defined as an ongoing state of nonconvulsive seizure or multiple nonconvulsive seizures without return to baseline for at least 30 minutes (73). A consensus working group refined the definition to account for the heterogeneous etiology, phenomenology, and prognosis of nonconvulsive status epilepticus (78). This definition incorporates elements of time (termed T1 and T2) and four additional axes (semiology, etiology, EEG correlate, and age). T1 indicates when seizures need to be acutely treated (eg, 10 minutes for focal status epilepticus with impaired awareness and 10 to 15 minutes for absence status epilepticus), and T2 indicates the time at which the likelihood of permanent neuronal injury increases and more aggressive therapy may be justified (more than 60 minutes for focal status epilepticus with impaired awareness and unknown for absence status epilepticus). However, this proposal does not account for age-related differences in the occurrence of T2, where experimental evidence and data from the FEBSTAT trial suggest that the immature brain is less likely to develop permanent injury than the adult brain (45; 52).
Clinical manifestations
Presentation and course
|
• The most common manifestation of nonconvulsive status epilepticus is impairment of consciousness. | |
|
• Hospitalized patients may have an assortment of subtle clinical findings including ocular movement abnormalities, myoclonus, and intermittent focal or multifocal movements. |
In a systematic review of nonconvulsive status epilepticus symptoms, the most common manifestation was impairment of consciousness, which occurred in 82% of patients (72). This altered consciousness could manifest as confusion (49%), coma (22%), lethargy (21%), and memory loss (18%).
Absence status epilepticus, sometimes considered a type of nonconvulsive status epilepticus, can be characterized by confusion, psychomotor retardation, and abnormal behavior (impulsivity, agitation, or aggression) (21; 72). These symptoms may start or end with a generalized convulsion (21). Absence status epilepticus is predominantly seen in ambulatory patients and the presentation and management is unique from other forms of nonconvulsive status epilepticus. Absence status is, thus, discussed in detail in a separate dedicated report.
Focal status epilepticus with impaired awareness is often reported as an “epileptic twilight state” with impaired responsiveness or confusion and bizarre behavior. Patients may also have automatisms (oral or manual) (21). Focal status epilepticus with intact awareness symptoms reflects the function associated with the ictal focus; common manifestations may include fear, mood changes, autonomic fluctuations, aversive eye movements, prolonged paralysis, or disturbed spatial perception simulating transient ischemic attacks (21; 72). Additional focal neurologic deficits have been reported, including aphasia, prosoposagnosia, catatonia, and catalepsy (03; 30; 59; 60).
Hospitalized patients with nonconvulsive status epilepticus may manifest other subtle clinical findings apart from altered mental status. Ocular movement abnormalities (sustained eye deviation, nystagmus, eye jerks), subtle myoclonic and intermittent focal or multifocal movements, and hippus increase the likelihood of nonconvulsive status epilepticus (74; 76; 38). None of these symptoms are specific for nonconvulsive status epilepticus, and an EEG is needed to confirm the diagnosis. Risk factors for nonconvulsive seizure activity in the critically ill include coma, history of epilepsy, convulsive seizure prior to the EEG, and remote brain injury (38; 14).
EEG patterns associated with nonconvulsive seizure and nonconvulsive status epilepticus can be subtle, and in the last 2 decades several attempts have been made to establish diagnostic criteria. Based on previous criteria, an expert panel at the 4th London Innsbruck Colloquium on Acute Seizures in Salzburg, Austria proposed the working criteria for nonconvulsive status epilepticus in 2013 (04); the criteria were later refined in 2015 (Table 1) (44). The modified criteria also used the standardized terminology established by the American Clinical Neurophysiology Society (33). However, in the setting of status epilepticus, these patterns may fall in the ictal-interictal continuum category, making a diagnosis of nonconvulsive status epilepticus even more difficult (12). Because of this uncertainty, a trial of benzodiazepines or rapid acting intravenous nonbenzodiazepine antiseizure medication during EEG recording can be helpful. The test is considered diagnostic for nonconvulsive status epilepticus only if there is resolution of the periodic EEG pattern and improvement in mental status; improvement in EEG without a clinical change is considered an indeterminant response (40; 37). Clinical improvement might take up to 24 hours in the critically ill patient with nonconvulsive status epilepticus (23).
Neonatal nonconvulsive status epilepticus is a common finding among critically ill neonates. Due to its unique clinical and electrophysiologic characteristics, as well as specialized management considerations, neonatal status epilepticus will be discussed in detail in a separate dedicated article.
Table 1. Modified Salzburg Consensus Criteria for Nonconvulsive Status Epilepticus
|
EEG data. EEG changes fulfilling the criteria must be continuously present for 10 or more seconds. Criteria are not applicable to physiological graphoelements. | ||
|
(A) Patients without known epileptic encephalopathy (at least ONE of criteria 1 through 3 should be fulfilled for diagnosis of nonconvulsive status epilepticus) | ||
|
(1) Epileptiform discharges greater than 2.5 Hz (ie, more than 25 epileptiform discharges in “worst” 10-second epoch) | ||
|
(2) Typical ictal spatiotemporal evolution* of: | ||
|
(2a) Epileptiform discharges OR | ||
|
(3) Subtle ictal clinical phenomena*** with: | ||
|
(3a) Epileptiform discharges OR | ||
|
(4) If criteria 1 to 3 are not fulfilled, but one of the following patterns is present, apply appropriate antiseizure medications after careful consideration of clinical situation and document response****: | ||
|
(4a) Epileptiform discharges 2.5 Hz or lower with fluctuation***** OR | ||
|
(B) Patients with known epileptic encephalopathy. In addition to the criteria above (A), these patients have to fulfill one of the following: | ||
|
• Increase in prominence or frequency when compared to baseline with observable change in clinical state | ||
|
Clinical data. Add clinical information for establishing the diagnosis of nonconvulsive status epilepticus: | ||
|
• Transition from premorbid to current ill state within minutes to hours. | ||
|
* Incrementing onset (increase in voltage and change in frequency) or evolution in pattern (change in frequency greater than 1 Hz and change in location) or decrementing termination (voltage and frequency) AND ACNS criterion for “evolving” (ACNS-evolving) ** ACNS criterion for rhythmic delta activity (ACNS-RDA) *** Minor twitching of mouth, periorbital region, or extremities should appear in close temporal relation to EEG pattern (be cautious concerning nonepileptic involuntary movements as mimics, eg, Parkinsonian tremor, drug-induced myoclonus, serotonin syndrome). **** Reactivity to intravenous antiseizure medications within 10 minutes after antiseizure medication fully applied. Clinical presentation tested: improvement is defined as better performance in 1 of 5 domains: (i) “say your surname,” (ii) “repeat 1,2,3,” (iii) “raise your arms” (first tell, if no response demonstrate), (iv) patient opens eyes to i–iii, and (v) patient looks at the examiner in response to i to iii. If no response, repeat procedure after strong tactile stimuli on both sides of the body. | ||
|
EEG tested: improvement is defined as reduction to “occasional”, ie, 1% to 9% of epoch. | ||
|
Document response: | ||
|
• No EEG improvement and no clinical improvement | ||
|
For clinical practice: all four constellations qualify for nonconvulsive status epilepticus. For research projects: patient qualifies for nonconvulsive status epilepticus if EEG or clinical improvement is documented, provided the clinical context is also in concordance with that. ***** ACNS criterion for fluctuation (ACNS-fluctuation) (44) | ||
Prognosis and complications
Nonconvulsive status epilepticus is a broad term that includes different groups of patients, and incidence and outcome estimates vary significantly in the literature. Ambulatory nonconvulsive status epilepticus typically represents an exacerbation of a seizure subtype or is the initial manifestation of a subacute neurologic insult and is typically associated with a favorable outcome. The prognosis is best for patients with preexisting genetic generalized epilepsy or de novo absence status epilepticus (48).
Hospitalized patients with nonconvulsive status epilepticus and coma have a much poorer prognosis. Symptomatic nonconvulsive seizure and nonconvulsive status epilepticus (after acute or remote brain injury) are associated with a longer hospital stay and high mortality rates (approximately 70%) (25). Some of this poor outcome may be due to the underlying cause of nonconvulsive status epilepticus and from the complications occurring in the clinical course. However, this association persists after controlling for age, etiology, neurologic exam, and organ dysfunction (17; 25). There are data to support the use of the ACD scoring measure to predict long-term mortality. This scoring system is named based on its inclusion of three key factors: age at onset, level of consciousness on admission, and duration of status epilepticus (64).
In comatose patients with subtle status epilepticus following convulsive status epilepticus, the resolution of the EEG discharges is associated with better outcome (75). Following the cessation of convulsive status epilepticus, normal EEG, burst suppression, after-status epilepticus ictal discharges (not including periodic lateralized epileptiform discharges), and periodic lateralized epileptiform discharges were associated with mortalities of 0%, 59%, 41%, and 40%, respectively (39). Additionally, in the Veteran Affairs Cooperation Study on the treatment of status epilepticus, 30-day outcome was significantly worse for patients with subtle status epilepticus than that with clinically overt generalized convulsive status epileptics (hospital discharged 50% vs. 8.8%; mortality 27% vs. 65%) (76).
Nonconvulsive seizures and status epilepticus may lead to secondary neuronal injury in critically ill patients. For instance, nonconvulsive status epilepticus and nonconvulsive seizure can cause hippocampal atrophy in patients with traumatic brain injury (81) and are associated with elevation in markers of brain injury measured using cerebral microdialysis (glutamate and lactate to pyruvate ratio) (82). Nonconvulsive status epilepticus in patients with intracranial hemorrhage has been associated with hematoma expansion (13) and in patients with subarachnoid hemorrhage and traumatic brain injury has been associated with transient brain hypoxia, metabolic crisis, increased intracranial pressure, and worse outcome (84; 18; 83). Despite these data, we should emphasize that nonconvulsive status epilepticus should not be considered a hopeless condition as some patients, after weeks to months of treatment, still recover with good outcomes (23; 43).
Clinical vignette
A 30-year-old woman started to complain of headache, altered mental status, and visual changes 3 days after cesarean section. Her physical examination was remarkable for decreased alertness, disorientation, and left hemianopsia. cEEG showed very frequent 5- to 10-minute-long electrographic seizures arising from the right posterior quadrant, maximal at O2, and focal slowing and attenuation in the same region. MRI revealed increased FLAIR and diffusion signal in the right temporal and occipital lobe. The patient was diagnosed with posterior reversible encephalopathy syndrome. She was treated with antihypertensive agents, magnesium, and levetiracetam with subsequent resolution of her symptoms.
Posterior reversible encephalopathy syndrome in adult (EEG and MRI)
(A) Continuous EEG recording demonstrating an electrographic seizure arising from the right posterior quadrant, maximal at O2. (B) MRI demonstrating increased FLAIR signal in the right occipito-temporal cortex, consistent with a d...
Biological basis
|
• Status epilepticus is thought to be due to the failure of endogenous CNS mechanisms to terminate a seizure. | |
|
• Prolonged seizures lead to numerous biochemical and neuronal cell changes over time that promote the ongoing seizure state. |
Localization
Localization is highly variable, but a focal process is probably involved in most cases, even when the EEG appears to be generalized. Preliminary perfusion CT evidence suggests that hyperperfused cortical areas can be identified during nonconvulsive status epilepticus but are not seen in other postictal settings (85). Also, a study showed focal, regional, or diffuse areas of F-2-fluoro-2-deoxy-D-glucose (FDG) uptake on brain PET in patients with periodic EEG patterns (70).
Etiology and pathogenesis
The etiology of nonconvulsive status epilepticus varies by case. For many patients with preexisting epilepsy, sudden discontinuation of antiseizure medicines can lead to presentation with convulsive or nonconvulsive status epilepticus.
Among critically ill patients, etiologies often include infectious, severe metabolic derangements, traumatic, ischemic, or hemorrhagic cerebrovascular events, increased intracranial pressure, and inflammatory disorders, among others (79).
Pathophysiology
There is little information on the mechanisms underlying nonconvulsive status epilepticus, with most of the prior literature investigating convulsive status epilepticus. Although the physiologic differences between convulsive and nonconvulsive status epilepticus are incompletely understood, there is likely significant overlap between the two. As such, we discuss the current data as they relate to convulsive status epilepticus and the insight they offer into the pathophysiology of nonconvulsive status epilepticus.
Animal studies of untreated status epilepticus have identified five discrete electrographic stages of continuous seizure activity: discrete electrographic seizures, waxing and waning seizures, continuous ictal discharges, ictal discharges with flat periods, and periodic epileptiform discharges (77). Some human studies have found a similar sequence, but others have not, perhaps due to treatment effects.
Status epilepticus is thought to be due to the failure of endogenous CNS mechanisms to terminate a seizure. Animal models have provided the most insight into the roles of various neurotransmitters and their receptors in status epilepticus. GABA, glutamate, NMDA receptors, acidosis, Na-K-ATP’ase, potassium, adenosine, opioids, neuropeptide Y, substance P, and other factors have all been implicated in mediating seizure termination (50). For instance, adenosine is an endogenous anticonvulsant and may contribute to seizure cessation and the postictal state (05). Murine studies suggest that the adenosine A1 receptor has an important role in restricting seizure spread (05). Indeed, most animal knockouts involving adenosine receptor pathways display profound aggravation of status epilepticus (02; 41). In addition, prolonged seizures can also lead to the internalization of GABA-A receptors, thereby altering the balance of excitation and inhibition in neuronal circuits, promoting self-sustaining mechanisms and resistance to benzodiazepines as status epilepticus progresses (32). The accumulation of intracellular chloride or higher bicarbonate permeability may also play a role in the loss of GABA mediated inhibition (11). At the same time, prolonged seizures can lead to increased trafficking of AMPA and NMDA receptor subunits from intracellular stores to the cell surface, thereby altering the balance of excitation and inhibition in neuronal circuits (54). Periodic discharges are thought to involve oscillatory corticothalamic pathways that are unmasked when cortical inhibition is lost (08). They are likely to utilize some of the same subcortical-cortical projection pathways as sleep transients (K-complexes, spindles, and vertex waves) and arousal (including the upper brainstem), explaining why they are sometimes exacerbated by alerting stimuli (34). Metabolic abnormalities may play a role in mediating cortical hyperexcitability as well (56).
Seizures are terminated by various mechanisms acting at the membrane, local network, and remote level. Subcortical brain regions, particularly the substantia nigra pars reticulata (SNR), have been shown to have an important role in seizure termination. The SNR is positioned anatomically to receive seizure activity originating in the neocortical hemispheres and then can exhibit back inhibitory impulses via the thalamus, superior colliculus, and pedunculopontine nucleus in the rostral brainstem. Data from animal models show that prolonged seizures and status epilepticus may in fact impair the ability of the SNR to terminate seizures, further contributing to an ongoing epileptic state (42).
Epidemiology
|
• The incidence of nonconvulsive status epilepticus ranges from 2 to 20 cases per 100,000. | |
|
• A significant number of critically ill patients with altered consciousness and no clinical signs of seizure have been found to be in nonconvulsive status epilepticus. |
The estimated incidence for status epilepticus is 10 to 41 per 100,000 per year; 5% to 49% of these cases are absence status epilepticus, focal status epilepticus with or without impaired awareness, and nonconvulsive status epilepticus in coma (49). According to the subtypes, from all forms of status epilepticus, 1% to 6% is absence status epilepticus in adults, 9% to 23% is focal status epilepticus with intact awareness, and 16% to 43% is focal status epilepticus with impaired awareness. These numbers are a compilation of multiple studies, and it should be noted that the incidence varies broadly due to the heterogeneous definitions and diagnostics criteria. The researchers also reported that the incidence of nonconvulsive status epilepticus ranges from 2 to 20 cases per 100,000, and 10% of the elderly with a protracted confusion will have late onset de novo absence status epilepticus (49).
In the hospital setting, nonconvulsive status epilepticus has been found to account for up to 20% of all cases of status epilepticus in general hospitals and up to 47% in the intensive care unit. Additionally, more than one third of patients in the emergency department and 8% in the intensive care unit with altered consciousness and no clinical signs of seizure were found to be in nonconvulsive status epilepticus detected by EEG (62; 72; 73).
The incidence of nonconvulsive seizure and nonconvulsive status epilepticus in children and neonate patients who were admitted to the intensive care unit, has been reported as 10% to 40% and 14% to 30%, respectively. In children, convulsive seizure or status epilepticus prior to starting EEG monitoring, structural brain injury, and several electrographic patterns (interictal or periodic epileptiform discharges, absence of background reactivity, and abnormal EEG background) increases the risk for nonconvulsive seizure.
Nonconvulsive status epilepticus is common among critically ill neonates and will be discussed in detail in a separate report.
Prevention
Among ambulatory patients with a diagnosis of epilepsy, adherence to antiseizure medication regimens is an important cornerstone in the prevention of status epilepticus of all types. For the majority of inpatient and critically ill patients, nonconvulsive status epilepticus is not usually preventable, and thus, management is usually focused on the rapid recognition, diagnosis, and treatment of status epilepticus when it occurs.
Differential diagnosis
Most nonconvulsive status epilepticus lacks obvious clinical manifestations apart from an altered level of consciousness, and the differential diagnosis of nonconvulsive status epilepticus includes a broad range of causes of altered mental status, coma, and delirium, such as toxic-metabolic encephalopathy, psychiatric disorders, trauma, tumor, vascular disease, migraines, thalamic or brainstem strokes, and confusional states induced by many drugs (such as lithium, alcohol, or psychotropic medications). Using the broad definition, any patient with coma and no other signs could have nonconvulsive status epilepticus. A high level of suspicion is important for recognition of nonconvulsive status epilepticus, which is more common than previously recognized (27), and cEEG monitoring is important for all patients with coma related to brain injury or history of convulsive status epilepticus or unexplained mental status changes (15).
In recent years, nonconvulsive status epilepticus has been reported as the presenting symptom of infection with COVID-19, and thus viral testing in patients with status epilepticus should be considered when appropriate (53).
Confusing conditions
Subtle myoclonic movements may be seen in some cases of nonconvulsive status epilepticus and should be distinguished from nonepileptic myoclonus. Subcortical myoclonus (presumably brainstem-generated in most cases), also known as reticular myoclonus, is probably the most common alternative diagnosis, and both cortical epileptic and subcortical nonepileptic myoclonus can coexist, particularly after a hypoxic insult. Typically, epileptic myoclonus involves muscle groups with larger cortical representations, such as the face and hand, whereas nonepileptic, subcortical myoclonus tends to involve axial muscles, such as sternocleidomastoid or abdominal muscles, though this may be difficult to distinguish in practice (24). In patients with nonconvulsive status epilepticus following generalized convulsive status epilepticus, jerking or myoclonic movements are common and can be elicited by alerting stimulation (without clinical arousal) (80; 34). The myoclonus is not always directly correlated with EEG discharges, and these patients may have a mixed cortical and subcortical etiology of myoclonus, perhaps relating to both the underlying epileptogenic injury and secondary brain injury from prolonged status epilepticus or hypoxia. In addition, muscle twitching arising from the spinal cord, peripheral nerves, or muscle (including due to metabolic processes) can be confused with the twitching of status epilepticus; for example, we have seen clonus related to exaggerated deep-tendon reflexes mistaken for seizure activity. This type of tendon reflex clonus is usually at the ankle or wrist and can be both elicited and terminated by positional changes.
Cortical myoclonus can be caused by a wide spectrum of diseases, including progressive myoclonic epilepsy, juvenile myoclonic epilepsy, chronic postanoxic myoclonus (Lance-Adams syndrome), and others (58; 67). Metabolic encephalopathies including renal failure (uremia) and hepatic failure (asterixis, thought to be subcortical in origin) (66) as well as electrolyte, thyroid, and vitamin derangements can also be associated with myoclonus (06). Numerous forms of neurodegenerative diseases can demonstrate myoclonus, including Lewy body dementia, Creutzfeldt-Jakob, and Alzheimer disease (up to 50% of patients with Alzheimer disease will develop myoclonus) (09; 06). When trying to characterize myoclonic movements, correlating EEG and EMG can be useful but may require computerized timing measurements and averaging for definitive results. In cortical myoclonus, the EEG discharge will consistently precede the muscle jerk, and the order of contractions of muscles will proceed from rostral to caudal (including within the cranial nerve-innervated muscles). In typical brainstem (reticular) myoclonus, there may or may not be an EEG correlate. If one exists, the EEG-EMG correlation may be variable with either one preceding the other, and lower cranial nerve muscles tend to be the first to contract, particularly the sternocleidomastoid (if involved) (58; 67).
Electroencephalographic phenomenology. Controversy surrounds many of the EEG findings seen in nonconvulsive status epilepticus with respect to whether or not the electrographic patterns represent ictal or interictal activity. Specifically, EEG findings such as periodic lateralized discharges, bilateral independent periodic discharges, and generalized periodic discharges are often associated with status epilepticus and nonconvulsive status epilepticus. However, although sometimes clearly ictal (especially if they fulfill the clinical criteria outlined in Table 1), these patterns are often thought not to represent definite seizures (12). Standardized terminology for these equivocal patterns was published as a guideline by the American Clinical Neurophysiology Society and shown to have acceptable levels of inter-rater reliability (33; 28). The real question is not what to call these EEG patterns (though standardized terminology is required for further research), but which ones are contributing to impaired mental status, cause neuronal injury, and will affect outcomes--as which ones need to be treated and how aggressively to treat them. Cerebral microdialysis, biomarkers, animal studies, intracranial recordings, and carefully designed clinical and imaging studies might help answer these questions (65).
Associated and underlying disorders
This seizure type can occur in any condition in which convulsive status epilepticus occurs.
Diagnostic workup
|
• Video EEG is the main means for diagnosis of nonconvulsive status epilepticus. |
EEG or cEEG is paramount (in fact, required by most definitions) to establishing the diagnosis in a comatose or obtunded patient with suspected status epilepticus or subtle status epilepticus. cEEG monitoring for 24 hours detects up to 88% of seizures and another 5% and 7% are detected on monitoring days 2 and 3 (14).
In recent years, the use of rapid, bedside EEG including electrode caps or quick-apply headbands with limited EEG arrays have been successful in decreasing the length of time to diagnosis, particularly in centers with limited access to formal EEG (35; 47). Furthermore, for institutions that lack continuous video EEG, there is growing evidence that shorter duration studies still have clinical utility, with the majority of patients with nonconvulsive status epilepticus being identified within the first hour of EEG (19).
Although EEG remains the gold standard for the diagnosis of status epilepticus, many hospital systems are unable to obtain timely EEG monitoring. In the critical care setting, there is preliminary evidence that pupillometry with abnormal or asymmetric neurologic pupil indices may be a sign of concurrent nonconvulsive status epilepticus (31). In addition, numerous MRI changes can be seen during or as a result of focal nonconvulsive status epilepticus, including DWI abnormalities and cortical T2-weighted signal hyperintensity, which may provide evidence for ongoing or recent nonconvulsive status epilepticus (29). Although pupillometry and MRI can help support a diagnosis of nonconvulsive status epilepticus, they cannot definitively confirm the diagnosis and, thus, should be used only as an ancillary testing strategy if EEG monitoring is delayed.
Management
|
• Benzodiazepines are the recommended initial treatment for most forms of nonconvulsive status epilepticus. | |
|
• Second-line agents include phenytoin, valproate, levetiracetam, phenobarbital, and other intravenous antiseizure medications (16). | |
|
• Patients refractory to first- and second-line treatments often require continuous anesthetic medications with appropriate cardiopulmonary support. |
In contrast to convulsive status epilepticus, there is no evidence-based treatment consensus for nonconvulsive status epilepticus due to a lack of randomized controlled trials. Most of the treatment recommendations come from expert opinions and are based off evidence originally studying the treatment of convulsive status epilepticus.
Similar, to convulsive status epilepticus, benzodiazepines are often recommended for initial treatment of most forms of nonconvulsive status epilepticus, including focal status epilepticus with impaired awareness and nonconvulsive status epilepticus in critically ill patients. Second-line agents may include nonsedating intravenous antiseizure medications such valproic acid, fosphenytoin, phenytoin, topiramate, levetiracetam, and lacosamide (49; 36). Although fosphenytoin and valproate have traditionally been the most commonly used agents, newer drugs such as levetiracetam and lacosamide have gained increasing favor in more recent years given their similar efficacy and more favorable side effect profiles (10; 61). Because head-to-head data are lacking, the choice of which antiseizure medication to use is frequently based on tolerability and safety as determined by a patient’s comorbidities and clinical status. Frequently, more than one antiseizure medication may be required, in which case combining various mechanisms of action is frequently recommended; however, evidence for improved efficacy is lacking. When intravenous medications are unavailable or are contraindicated, enteral options, usually administered crushed through a nasogastric tube, have been reported to be effective in some cases (07; 46). Because there are few or no clinical findings, treatment response is assessed by cEEG monitoring. Treatment should be advanced until improvement is seen in the EEG or the clinical condition of the patient. Correcting metabolic abnormalities or treating systemic infection may also improve nonconvulsive status epilepticus in some critically ill patients. In patients who fail to respond to the first nonsedating antiseizure medication, often a second nonsedating antiseizure medication is recommended.
In cases of focal status epilepticus with impaired awareness that fail to respond to nonsedating antiseizure medications at appropriate doses, use of continuous intravenous anesthetic agents (such as midazolam or propofol) should be considered with appropriate cardiopulmonary support (49).
In subtle status epilepticus following generalized convulsive status epilepticus, the EFNS guidelines suggest general anesthetic doses of sedatives or barbiturates achieving burst suppression on EEG for a minimum of 24 hours until therapeutic doses of antiseizure medications are initiated (48). There is significant controversy about how aggressively to treat nonconvulsive status epilepticus that is not associated with prior convulsive status epilepticus in critically ill patients (40; 48). Some authors advocate using additional intravenous anticonvulsants, such as levetiracetam, valproate, or phenobarbital, prior to proceeding to anesthetic agents (48) as use of intravenous anesthetic may be associated with increased mortality risk (71).
Continuous EEG is increasingly used in critically ill patients with altered mental status to screen for nonconvulsive status epilepticus and nonconvulsive seizure though there is limited evidence that this test leads to improved outcomes. A retrospective cross-sectional study conducted to analyze cost-effectiveness and outcome of cEEG monitoring showed that the use of cEEG in the intensive care unit was associated with decreased in-hospital mortality in mechanically ventilated patients, without adding cost to the hospital stay compared to routine EEG (57). Novel risk prediction scores based on clinical and EEG findings may help optimize patient selection and duration of monitoring to improve cost-effectiveness (68; 69).
For the most refractory of cases, novel approaches with immunotherapy, steroids, ketamine, ketogenic diet, neurostimulation, and even targeted surgery can be considered (63; 20).
Outcomes
Concluding comments. Nonconvulsive status epilepticus has many subtypes that can be seen in the ambulatory and inpatient setting. The diagnosis of nonconvulsive status epilepticus should be considered when a patient with history of seizures and altered mental status is encountered in the clinic or if a patient is not back to his baseline after convulsive seizures, especially if neuroimaging or laboratory analysis do not provide an equivocal etiology for altered mental status. Nonconvulsive status epilepticus should also be considered in any critically ill patient with coma or fluctuating mental status, especially if they have a history of acute or remote brain injury. cEEG should be performed for at least 24 to 48 hours, and a trial of benzodiazepine should be considered when EEG discharges don’t meet electrographic nonconvulsive seizure criteria. Lastly, there is no consensus in the management of nonconvulsive status epilepticus, and therapy should be tailored to patient clinical history, presentation, and EEG finings.
A number of prognostic tools have been developed to predict outcomes after the treatment of status epilepticus, including the STESS (status epilepticus severity score), mSTESS (modified STESS), EMSE (epidemiology-based mortality score in status epilepticus), END-IT (encephalitis, NCSE, diazepam resistance, imaging features, and tracheal intubation), and SACE (seizures, age, coma, EEG evolution) (51). Features of these scoring systems are further detailed in Table 2.
Table 2. Scoring Systems
|
Tool |
Variables included |
Scoring |
Outcome prediction |
|
STESS |
• Level of consciousness |
0-6 |
STESS <3 ~97% NPV for mortality, poor neurologic outcome at discharge, and need for coma induction. STESS <2 with 100% NPV for mortality, poor neurologic outcome, and need for coma induction. |
|
mSTESS |
• Level of consciousness |
0-8 |
mSTESS >4 established 81.8% accuracy in predicting mortality. |
|
EMSE |
• Etiology of status epilepticus |
1-no limit |
EMSE >64 NPV 100% and PPV 69% for death. |
|
END-IT |
• Presence of encephalitis |
0-6 |
END-IT ≥ 3 showed 82.8% NPV and 70.3% PPV for poor outcome (mRS ≥3). |
|
SACE |
• History of seizures |
0-5 |
SACE ≥ 3 was 77% sensitive and 74% specific in predicting in-hospital survival. |
|
| |||
Special considerations
Acknowledgement
This is one of several clinical summaries originally developed as official descriptions of epileptic seizures and syndromes under the auspices of the International League Against Epilepsy (ILAE) Task Force on Classification and Terminology. It is now maintained by MedLink by agreement with the ILAE and may no longer reflect the official position of the ILAE.
Media
References
- 01
- Abend N. Electrographic status epilepticus in critically ill children: epidemiology and outcome. Epilepsy Behav 2015;49:223-7. PMID 25944114
- 02
- Avsar E, Empson RM. Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy. Neuropharmacology 2004;47(3):427-37. PMID 15275832
- 03
- Azman F, Tezer FI, Saygi S. Aphasic status epilepticus in a tertiary referral center in Turkey: clinical features, etiology, and outcome. Epilepsy Res 2020;167:106479. PMID 33038720
- 04
- Beniczky S, Hirsch L, Kaplan P, et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013;54 Suppl 6:28-9. PMID 24001066
- 05
- Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 2008;84(3):249-62. PMID 18249058
- 06
- Borg M. Symptomatic myoclonus. Neurophysiol Clin 2006;36(5-6):309-18. PMID 17336775
- 07
- Bravo P, Vaddiparti A, Hirsch LJ. Pharmacotherapy for nonconvulsive seizures and nonconvulsive status epilepticus. Drugs 2021;81(7):749-70. PMID 33830480
- 08
- Brenner RP, Schaul N. Periodic EEG patterns: classification, clinical correlation, and pathophysiology. J Clin Neurophysiol 1990;7(2):249-67. PMID 2187023
- 09
- Caviness JN. Myoclonus and neurodegenerative disease--what's in a name. Parkinsonism Relat Disord 2003;9(4):185-92. PMID 12618052
- 10
- Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci 2015;22(6):959-63. PMID 25899652
- 11
- Chen JW, Wasterlain C. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5(3):246-56.** PMID 16488380
- 12
- Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill. Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005;22(2):79-91. PMID 15805807
- 13
- Claassen J, Jette N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology 2007;69(13):1356-65. PMID 17893296
- 14
- Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004;62(10):1743-8. PMID 15159471
- 15
- Claassen J, Perotte A, Albers D, et al. Nonconvulsive seizures after subarachnoid hemorrhage: multimodal detection and outcomes. Ann Neurol 2013;74(1):53-64. PMID 23813945
- 16
- Dalrymple RA. Phenytoin and levetiracetam are equally effective second-line treatments for status epilepticus. Arch Dis Child Educ Pract Ed 2020;105(5):319-20. PMID 31826874
- 17
- DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39(8):833-40. PMID 9701373
- 18
- De Marchis G, Pugin D, Meyers E, et al. Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology 2016;86(3):253-60. PMID 26701381
- 19
- Dericioglu N, Arsava EM, Topcuoglu MA. Time to detection of the first seizure in patients with nonconvulsive status epilepticus in the neurological intensive care unit. Clin EEG Neurosci 2020;51(1):70-3. PMID 31533458
- 20
- Dhaliwal J, Ganguly R, Mindel J, Krishna V. VNS stopping anti-NMDA receptor encephalitis-triggered nonconvulsive status epilepticus. World Neurosurg 2021;146:364-6. PMID 33091646
- 21
- Drislane FW. Presentation, evaluation, and treatment of nonconvulsive status epilepticus. Epilepsy Behav 2000;1(5):301-14. PMID 12609161
- 22
- Drislane FW, Kaplan P. Nonconvulsive status epilepticus. 1st ed. Demos Medical Publishing, 2008.
- 23
- Drislane FW, Lopez MR, Blum AS, Schomer DL. Detection and treatment of refractory status epilepticus in the intensive care unit. J Clin Neurophysiol 2008;25(4):181-6. PMID 18677181
- 24
- Faught E. Clinical presentations and phenomenology of myoclonus. Epilepsia 2003;44 (Suppl 11):7-12. PMID 14641566
- 25
- Ferguson M, Bianchi M, Sutter R, et al. Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus. Neurocritical Care 2013;18(2):216–27. PMID 23065689
- 26
- Foreman B, Hirsch LJ. Epilepsy emergencies: diagnosis and management. Neurol Clin 2012; 30(1):11-41. PMID 22284053
- 27
- Friedman D, Claassen J, Hirsch LJ. Continuous electroencephalogram monitoring in the intensive care unit. Anesth Analg 2009;109(2):506-23. PMID 19608827
- 28
- Gaspard N, Hirsch LJ, LaRoche SM, Hahn CD, Westover MB; Critical Care EEG Monitoring Research Consortium. Interrater agreement for critical care EEG terminology. Epilepsia 2014;55(9):1366-73. PMID 24888711
- 29
- Gelisse P, Genton P, Crespel A, Lefevre PH. Will MRI replace the EEG for the diagnosis of nonconvulsive status epilepticus, especially focal? Rev Neurol (Paris) 2021;177(4):359-69. PMID 33487411
- 30
- George RS, Sadler RM, Clarke DB. An unusual Todd's phenomenon: post-ictal prosopagnosia. Can J Neurol Sci 2021;48(5):730-1. PMID 33272342
- 31
- Godau J, Bharad K, Rösche J, et al. Automated pupillometry for assessment of treatment success in nonconvulsive status epilepticus. Neurocrit Care 2022;36(1):148-9. PMID 34331202
- 32
- Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci 2005;25(23):5511-20. PMID 15944379
- 33
- Hirsch LJ, LaRoche SM, Gaspard N, et al. American clinical neurophysiology society's standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol 2013;30(1):1-27. PMID 23377439
- 34
- Hirsch LJ, Pang T, Claassen J, et al. Focal motor seizures induced by alerting stimuli in critically ill patients. Epilepsia 2008;49(6):968-73. PMID 18177364
- 35
- Hobbs K, Krishnamohan P, Legault C, et al. Rapid bedside evaluation of seizures in the ICU by listening to the sound of brainwaves: a prospective observational clinical trial of Ceribell's brain stethoscope function. Neurocrit Care 2018;29(2):302-12. PMID 29923167
- 36
- Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013;54(3):393-404. PMID 23293881
- 37
- Hopp J, Sanchez A, Krumholz A, Hart G, Barry E. Nonconvulsive status epilepticus value of a benzodiazepine trial for predicting cutcomes. Neurologist 2011;29(1):65-72. PMID 22045283
- 38
- Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003;74(2):189-91. PMID 12531946
- 39
- Jaitly R, Sgro JA, Towne AR, Ko D, DeLorenzo RJ. Prognostic value of EEG monitoring after status epilepticus: a prospective adult study. J Clin Neurophysiol 1997;14(4):326-34. PMID 9337142
- 40
- Jirsch J, Hirsch LJ. Nonconvulsive seizures: Developing a rational approach to the diagnosis and management in the critically ill population. Clin Neurophysiol 2007;118(8):1660-70. PMID 17588812
- 41
- Kochanek PM, Hendrich KS, Jackson EK, et al. Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging. J Cereb Blood Flow Metab 2005;25(12):1596-612. PMID 15931163
- 42
- Lado FA, Moshé SL. How do seizures stop? Epilepsia 2008;49(10):1651-64. PMID 18503563
- 43
- Lai A, Outin H, Jabot J, et al. Functional outcome of prolonged refractory status epilepticus. Crit Care 2015;19:199. PMID 25925042
- 44
- Leitinger M, Trinka E, Gardella E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 2016;15(10):1054-62.** PMID 27571157
- 45
- Lewis DV, Shinnar S, Hesdorffer DC, et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann Neurol 2014;75(2):178-85. PMID 24318290
- 46
- Lim SN, Wu T, Tseng WJ, et al. Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review. J Neurol 2021;268(10):3744-57. PMID 33754209
- 47
- McKay JH, Feyissa AM, Sener U, et al. Time is brain: the use of EEG electrode caps to rapidly diagnose nonconvulsive status epilepticus. J Clin Neurophysiol 2019;36(6):460-6. PMID 31335565
- 48
- Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010;17(3):348-55. PMID 20050893
- 49
- Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol 2007;6(4):329-39. PMID 17362837
- 50
- Mello LE, Covolan L, Hamani C, Smith RL. Excitotoxicty in status epilepticus. In: Wasterlain CG, Treiman, DM, editors. Status Epilepticus: Mechanisms and Management. Cambridge, MA: MIT Press, 2006:327-37.
- 51
- Misirocchi F, Zilioli A, Mannini E, et al. Prognostic value of Salzburg nonconvulsive status epilepticus criteria: The SACE score. Epilepsia 2024;65(1):138-47. PMID 37965804
- 52
- Molinero I, Galanopoulou AS, Moshé SL. Rodent models: where it all started with these "truths". Eur J Paediatr Neurol 2020;24:61-5. PMID 31875833
- 53
- Moorthamers S, Preseau T, Sanoussi S, Gazagnes MD. COVID-19 masquerading as a non-convulsive status epilepticus. Int J Emerg Med 2022;15:3. PMID 35079294
- 54
- Naylor DE, Liu H, Niquet J, Wasterlain CG. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 2013;54:225-38. PMID 23313318
- 55
- Neligan A, Shorvon SD. The history of status epilepticus and its treatment. Epilepsia 2009;50 Suppl 3:56-68. PMID 19298433
- 56
- Neufeld MY, Vishnevskaya S, Treves TA, et al. Periodic lateralized epileptiform discharges (PLEDs) following stroke are associated with metabolic abnormalities. Electroencephalogr Clin Neurophysiol 1997;102(4):295-8. PMID 9146489
- 57
- Ney JP, Van Der Goes D, Nuwer M, Nelson L, Eccher M. Continuous and routine EEG in intensive care: utilization and outcomes, United States 2005-2009. Neurology 2013;81(23):2002-8. PMID 24186910
- 58
- Obeso JA, Rothwell JC, Marsden CD. The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain 1985;108(Pt 1):193-24. PMID 3919883
- 59
- Ogyu K, Kurose S, Uchida H, Kanemoto K, Mimura M, Takeuchi H. Clinical features of catatonic non-convulsive status epilepticus: a systematic review of cases. J Psychosom Res 2021;151:110660. PMID 34768095
- 60
- Orlando B, Morano A, Cerulli Irelli E, Fanella M, Giallonardo AT, Di Bonaventura C. Unilateral catalepsy in non-convulsive status epilepticus. Epileptic Disord 2021;23(5):760-4. PMID 34609287
- 61
- Panda PK, Panda P, Dawman L, Sharawat IK. Efficacy of lacosamide and phenytoin in status epilepticus: a systematic review. Acta Neurol Scand 2021;144(4):366-74. PMID 33999428
- 62
- Privitera M, Strawsburg R. Electroencephalographic monitoring in the emergency department. Emerg Med Clin North Am 1994;12(4):1089-100. PMID 7956889
- 63
- Rai S, Drislane F. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics 2018;15(3):697-712. PMID 29922905
- 64
- Roberg LE, Monsson O, Kristensen SB, et al. Prediction of long-term survival after status epilepticus using the ACD score. JAMA Neurol 2022;79(6):604-13. PMID 35404392
- 65
- Rubinos C, Reynolds AS, Claassen J. The ictal-interictal continuum: to treat or not to treat (and how)? Neurocrit Care 2018;29(1):3-8. PMID 29139014
- 66
- Shibasaki H. Physiology of negative myoclonus. Adv Neurol 2002;89:103-13. PMID 11968435
- 67
- Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve 2005;31(2):157-74. PMID 15547927
- 68
- Struck AF, Osman G, Rampal N, et al. Time-dependent risk of seizures in critically ill patients on continuous electroencephalogram. Ann Neurology 2017a;82(2):177-85. PMID 28681492
- 69
- Struck AF, Ustun B, Ruiz AR, et al. Association of an electroencephalography-based risk score with seizure probability in hospitalized patients. JAMA Neurol 2017b;74(12):1419-24. PMID 29052706
- 70
- Struck AF, Westover MB, Hall LT, Deck GM, Cole AJ, Rosenthal ES. Metabolic Correlates of the Ictal-Interictal Continuum: FDG-PET During Continuous EEG. Neurocrit Care 2016;24(3):324-31. PMID 27169855
- 71
- Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014;82(8):656-64. PMID 24319039
- 72
- Sutter R, Rüegg S, Kaplan PW. Epidemiology, diagnosis, and management of nonconvulsive status epilepticus: opening Pandora’s box. Neurology 2012;2(4):275-86. PMID 30123679
- 73
- Sutter R, Semmlack S, Kaplan PW. Nonconvulsive status epilepticus in adults--insights into the Invisible. Nat Rev Neurol 2016;12(5):281-93. PMID 27063108
- 74
- Treiman DM. Electroclinical features of status epilepticus. J Clin Neurophysiol 1995;12(4):343-62.** PMID 7560022
- 75
- Treiman DM. Subtle generalized convulsive status epilepticus. Epilepsia 1984;25:653.
- 76
- Treiman DM, Meyers PD, Wallton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-98. PMID 9738086
- 77
- Treiman DM, Walton NY, Kendrick C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 1990;5(1):49-60. PMID 2303022
- 78
- Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015;56(10):1515-23.** PMID 26336950
- 79
- Valton L, Benaiteau M, Denuelle M, et al. Etiological assessment of status epilepticus. Rev Neurol (Paris) 2020;176(6):408-26. PMID 32331701
- 80
- Van Cott AC, Blatt I, Brenner RP. Stimulus-sensitive seizures in postanoxic coma. Epilepsia 1996;37(9):868-74. PMID 8814100
- 81
- Vespa P, McArthur DL, Xu Y, et al. Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy. Neurology 2010;75(9):792-8. PMID 20805525
- 82
- Vespa P, Prins M, Ronne-Engstrom E, et al. Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. J Neurosurg 1998;89(6):971-82. PMID 9833824
- 83
- Vespa P, Tubi M, Claassen J, et al. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol 2016;79(4):579-90. PMID 26814699
- 84
- Vespa P, Miller C, McArthur D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 2007;35(12):2830-6. PMID 18074483
- 85
- Wiest R, von Bredow F, Schindler K, et al. Detection of regional blood perfusion changes in epileptic seizures with dynamic brain perfusion CT--a pilot study. Epilepsy Res 2006;72(2-3):102-10. PMID 17118628
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Jonathan M Gursky MD
Dr. Gursky of Montefiore Medical Center/Albert Einstein College of Medicine received a consulting fee from Epitel.
See Profile
Editor
-
Solomon L Moshé MD
Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile
Former Authors
- Nishi Rampal MD
- Lawrence J Hirsch MD
- Clio Rubinos MD
- Daniel Friedman MD
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- No sex preponderance.
- Heredity
-
- No hereditary factors.
- Population groups selectively affected
-
- No population group selectively affected.
- Occupation groups selectively affected
-
- No occupation group selectively affected.
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Epilepsy & Seizures
Intermittent explosive disorder
Nov. 11, 2024
-
Epilepsy & Seizures
Pyridoxine/P5P-dependent developmental epileptic encephalopathy
Oct. 14, 2024
-
Epilepsy & Seizures
Reflex seizures
Oct. 04, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Epilepsy & Seizures
Self-limited (familial) neonatal epilepsy
Oct. 02, 2024
-
Epilepsy & Seizures
Epilepsy with auditory features
Oct. 01, 2024
-
Epilepsy & Seizures
Alcohol withdrawal seizures
Sep. 16, 2024